

**JEREMY M. VAN RAAMSDONK, Ph.D.**  
Residency Status: US Permanent Resident

**Current Positions**

Assistant Professor and Head of Laboratory of Aging and Neurodegenerative Disease  
Center for Neurodegenerative Science, Van Andel Research Institute

Assistant Professor, Department of Genetics, Michigan State University

Assistant Professor, Department of Translational Science and Molecular Medicine, Michigan State University

**Contact Details**

Van Andel Research Institute

333 Bostwick Avenue NE

Grand Rapids, Michigan 49503

Phone: W (616)234-5594

Email: [jeremy.vanraamsdonk@vai.org](mailto:jeremy.vanraamsdonk@vai.org)

Website: [www.vai.org](http://www.vai.org)

---

**EDUCATION**

**Postdoctoral Fellowship in Biology**, McGill University, Supervisor: Siegfried Hekimi

**Ph.D. in Medical Genetics** (2005), University of British Columbia, Supervisor: Michael Hayden

**M.Sc. in Medical Sciences** (1999), McMaster University, Supervisor: Patricia Chang

**B.Sc.(Honours) in Biochemistry** (1997), University of British Columbia, Supervisor: Pat Dennis

---

**HONOURS**

- |         |  |
|---------|--|
| 2011    | Canadian Institutes of Health Research Institute of Aging Travel Award   |
| 2009    | Canadian Institutes of Health Research Institute of Aging Age Plus Award   |
| 2007    | Child and Family Research Institute Outstanding Post-Doctoral Achievement Award<br><i>- award for the best post-doctoral researcher</i>  |
| 2007-10 | Milton Wexler Post-Doctoral Fellowship award from Hereditary Disease Foundation<br><i>- fellowship award given to the top ranked post-doctoral applicant</i>                           |
| 2007    | Canadian Institutes of Health Research Institute of Aging Special Recognition Fellowship<br><i>- award for the top ranked post-doctoral application in the CIHR Institute of Aging</i> |
| 2006    | Governor General's Gold Medal<br><i>- award for most outstanding graduate student in graduating class for the Doctoral degree</i>  |
| 2003-11 | CAG Gordon Conference Young Investigators Award (2003, 2005, 2009, 2011)   |
| 2001-02 | Kearns Award for HD Research<br><i>- award for excellence in Huntington disease research</i>   |
| 1996-97 | University of British Columbia Westbrook Scholar<br><i>- most prestigious designation at University of British Columbia for outstanding academics, leadership and involvement</i>      |
| 1993-97 | Dean's Honours List University of British Columbia   |
| 1994-96 | Science Scholar Designation<br><i>- for top 20 students in Science at University of British Columbia</i>   |
| 1994    | Hewlett-Packard Prize<br><i>- for top 10 students in Science at University of British Columbia</i>   |
| 1993    | Governor General's Bronze Medal<br><i>- for highest academic average in the graduating class</i>   |

---

**SCHOLARSHIPS AND FELLOWSHIPS**


---

2010-12	Parkinson Society Canada Basic Research Fellowship
2007-10	Canadian Institutes of Health Research Fellowship <b>- application ranked 1<sup>st</sup> in the nation in CIHR Institute of Aging</b>
2007-09	Tomlinson Fellowship from McGill University <b>- award for the top postdoctoral fellows at McGill University</b>
2004-05	Landmark Graduate Award for HD research
2001-04	Canadian Institutes of Health Research Doctoral Research Award <b>- application ranked 1<sup>st</sup> in the nation of 409 applicants</b>
2001-04	Michael Smith Foundation for Health Research Doctoral Trainee Award
1999-01	Natural Sciences and Engineering Research Council PGS B Scholarship
1999-01	University of British Columbia Faculty of Medicine Grant Supplement Award
1997-99	Natural Sciences and Engineering Research Council PGS A Scholarship
1997-99	McMaster Entrance Scholarship
1993-97	University of British Columbia Chancellor's Scholarship
1993-97	Canada Scholarship in Science and Engineering
1995-97	Charles and Jane Banks Scholarship for Science
1996-97	Canada Scholarship Corporate Award
1994-95	J. Fred Muir Scholarship in Science and Engineering
1993	British Columbia Provincial Scholarship

---

**RESEARCH EXPERIENCE**


---

2007-2012	Department of Biology, McGill University, Montreal, Quebec Supervisor: Siegfried Hekimi Topic: The role of oxidative stress in aging and neurodegenerative disease
2006	Centre for Molecular Medicine and Therapeutics, Vancouver, B.C. Supervisor: Blair Leavitt Topic: Pathogenesis and treatment of Huntington disease
2000-2005	Department of Medical Genetics, University of British Columbia, Vancouver, B.C. Supervisor: Michael Hayden Topic: Characterization of treatment of mouse models of Huntington disease
2001	Lausanne Medical School, Surgical Research and Gene Therapy, Lausanne, Switzerland Supervisors: Patrick Aebischer, Nicole Deglon Topic: Lentiviral gene therapy for treatment and generation of mouse models
1999-2000	British Columbia Cancer Agency, Vancouver, B.C. Supervisor: Peter Lansdorp Topic: Telomerase, telomeres and cellular longevity
1997-1999	Department of Medical Sciences, McMaster University, Hamilton, Ontario Supervisor: Patricia Chang Topic: An alternative form of gene therapy for the treatment of Hemophilia B
1996-1997	Department of Biochemistry and Molecular Biology, UBC, Vancouver, B.C. Supervisor: Patrick Dennis Topic: Ribosomal RNA operons in halophilic bacteria
1996	Department of Microbiology and Biochemistry, University of Victoria, Victoria, B.C. Supervisor: Santosh Misra Topic: Resistance genes in plants

---

**TEACHING EXPERIENCE**


---

2014-15	Historical Perspectives in Biomedical Research: <i>C. elegans</i> , Instructor Strategic Approaches to Biomedical Research: Parkinson disease, Instructor
2013-14	Historical Perspectives in Biomedical Research: <i>C. elegans</i> , Instructor Strategic Approaches to Biomedical Research: Parkinson disease, Instructor
2012-13	Genetics, Van Andel Institute Graduate School, VAI 9010, Developer and Director Historical Perspectives in Biomedical Research: <i>C. elegans</i> , Instructor
2004-05	Molecular Genetics, University of British Columbia, Biology 335, Teaching Assistant
2003-04	Basic Genetics, University of British Columbia, Biology 334, Teaching Assistant
2002-03	Molecular Genetics, University of British Columbia, Biology 335, Teaching Assistant
2002-03	Basic Genetics, University of British Columbia, Biology 334, Teaching Assistant
2001-02	Molecular Genetics, University of British Columbia, Biology 335, Teaching Assistant
2000-01	Molecular Genetics, University of British Columbia, Biology 335, Teaching Assistant
1998-99	Human Biochemistry, McMaster University, HTH SCI 1A06, Teaching Assistant
1997-98	Human Biochemistry, McMaster University, HTH SCI 1A06, Teaching Assistant

---

**STUDENTS SUPERVISED**


---

2014-	Lindsey Cunningham	Graduate rotation student, Van Andel Institute Graduate School
2013-	Jason Cooper	Graduate student, Van Andel Institute Graduate School
2013-	Emily Machiela	Graduate student, Van Andel Institute Graduate School
2013-	Dylan Dues	Van Andel Research Institute
2013-14	Ugomma Eze	Undergraduate summer intern
2013-14	Claire Schaar	Undergraduate summer intern
2013-14	Katie Spielbauer	Medical student, Michigan State University
2013-14	Erin Weston	Graduate rotation student, Van Andel Institute Graduate School
2012-13	Agni Naidu	Graduate rotation student, Van Andel Institute Graduate School
2012-13	Keith Dufendach	Van Andel Research Institute
2012-13	Stephanie LeValley	Graduate rotation student, Michigan State University
2012-13	Emily Andrews	Undergraduate summer intern
2012-13	MacLane Watson	Undergraduate summer intern
2012-13	Alexis Bergsma	Graduate rotation student, Van Andel Institute Graduate School

---

**THESIS ADVISORY COMMITTEES**


---

2014-	Erin Weston	Advisor: Darren Moore
2014-	Emily Machiela	Advisor: Jeremy Van Raamsdonk
2013-	Erin Hildebrandt	Advisor: Patrik Brundin
2013-	Agni Naidu	Advisor: Nick Duesbery
2013-	Jason Cooper	Advisor: Jeremy Van Raamsdonk

---

**FORMAL TRAINING IN TEACHING**


---

2012	VAIGS Faculty Development Student Learning Workshop Series
2009	Introduction to Course Design and Teaching, McGill, Teaching and Learning Services
2009	Learning to Teach Workshop, McGill, Graduate and Postdoctoral Studies
2004	Problem Based Learning General Skills Tutor Training, UBC, Faculty of Medicine
1997	Teaching Assistant Workshop, McMaster University

---

**LEADERSHIP AND SERVICE**


---

2014-	Organizer of Michigan <i>C. elegans</i> Meeting
2013-	Van Andel Institute Graduate School Curriculum Committee
2013-	Steering committee for Research in Progress and Journal Club
2012-	Grand Challenges in Parkinson's Disease Symposium Scientific Program Committee
2012-	Head of Laboratory of Aging and Neurodegenerative Disease
2013-14	Chair of Council for Research Affairs, Van Andel Research Institute
2013-14	Van Andel Research Institute Council for Research Affairs (elected)
2013-14	Van Andel Research Institute Center for Neurodegenerative Science Faculty Search Committee
2013	Co-Chair of Session on Aging and Stress at International Worm Meeting
2012-13	Grand Challenges in Parkinson's Disease Symposium Organizing Committee
2012-13	Van Andel Research Institute Center for Neurodegenerative Science Faculty Search Committee
2012-13	Van Andel Research Institute Accreditation Committee
1999-04	Chair of Green College Athletic Committee, UBC Intramural Sports Representative
1997-99	Health Science Graduate Student Federation (HSGSF) Representative for Molecular Biology, Genetics and Cancer department, HSGSF Athletics and Social Chair
1996-97	Mentor in UBC's Mentor Program, UBC Intramural Sports Representative
1995-96	Representative for Totem Park Residents Association, UBC Intramural Sports Representative
1993-94	Biological Society (BIOSOC) 1st Year Representative at UBC

---

**PEER REVIEWER OF SCIENTIFIC JOURNALS AND GRANTS**


---

**Ad hoc reviewer of scientific manuscripts:**

<i>Nature Chemical Biology</i>	<i>International Journal of Molecular Sciences</i>
<i>PLoS Genetics</i>	<i>Journal of Gerontology</i>
<i>Aging Cell</i>	<i>Journal of Huntington Disease Research</i>
<i>Antioxidant and Redox Signaling</i>	<i>Journal of Neurochemistry</i>
<i>Chemistry &amp; Biology</i>	<i>Journal of Neuroscience</i>
<i>Experimental Gerontology</i>	<i>Mechanisms of Ageing and Development</i>
<i>FASEB Journal</i>	<i>PLoS ONE</i>
<i>Human Molecular Genetics</i>	<i>Movement Disorders</i>

**Ad hoc reviewer of research grants:**

Medical Research Council  
 Biotechnology and Biological Sciences Research Council

---

**CAREER DEVELOPMENT**


---

2013	Van Andel Research Institute GROW Professional Development Series
2009	Canadian Institutes of Health Research Summer Program in Aging (White Point, Nova Scotia)
2006	Short course in Medical and Experimental Mammalian Genetics organized by the Jackson Laboratory and Johns Hopkins University (Bar Harbor, Maine)


**SUMMARY OF PUBLICATIONS AND ABSTRACTS**

	First Author	Senior Author	Other Author	Total
<b>Total publications</b>	27	2	6	<b>35</b>
<b>Original research publications</b>	16	1	5	<b>22</b>
<b>Review publications</b>	4	0	1	<b>5</b>
<b>Mini-review publications</b>	7	1	0	<b>8</b>
<b>Abstracts</b>	24	7	10	<b>41</b>

**CITATION REPORT (December, 2014)**

**Total Citations:** 2375

**H-index:** 22 (number of papers with at least this number of citations)



**Summary for original research papers:**

**Times Cited:** 2153

**Average Citations per Item:** 102.5

## ORIGINAL RESEARCH PUBLICATIONS

1. Schaar CE, Dues DJ, Spielbauer KK, Machiela E, Cooper JF, Senchuk M, Hekimi S, **Van Raamsdonk JM** (2015). Mitochondrial and Cytoplasmic ROS Have Opposing Effects on Lifespan. *PLoS Genetics* (In Press). Impact: 8.694.
2. **Van Raamsdonk JM**, Hekimi S (2012). Superoxide dismutase is dispensable for normal animal lifespan. *Proc. Natl. Acad. Sci. USA*. 109(15):5785-90. Impact: 9.681, Cit: 84.  
**\*\*featured on cover and "In this Issue" journal highlights**  
**\*\*Recommended by Faculty of 1000**
3. **Van Raamsdonk JM**, Hekimi S (2011). FUDR causes a twofold increase in the lifespan of the mitochondrial mutant *gas-1*. *Mechanisms of Ageing and Development*. 132(10): 519-521. Impact: 3.439, Cit: 18.
4. **Van Raamsdonk JM**, Meng Y, Camp D, Yang W, Jia X, Bénard C, Hekimi S (2010). Decreased Energy Metabolism Extends Lifespan in *Caenorhabditis elegans* Without Reducing Oxidative Damage. *Genetics*. 185(2): 559-71. Impact: 4.007, Cit: 36.  
**\*\*featured in "Issue Highlights"**
5. **Van Raamsdonk JM**, Hekimi S (2009). Deletion of the Mitochondrial Superoxide Dismutase *sod-2* Extends Lifespan in *Caenorhabditis elegans*. *PLoS Genetics*. 5(2), e1000361. Impact: 8.694, Cit: 218.  
**\*\*24,472 article views**  
**\*\*featured in *Scientific American, Spiegel Online, Science Daily, En Tete, Futura-Sciences, McGill Science Update, Ministere Education Nationale France***  
**\*\*Recommended by Faculty of 1000**
6. **Van Raamsdonk JM**, Murphy Z, Selva DM, Hamidzadeh R, Pearson J, Petersen A, Bjorkqvist M, Muir C, MacKenzie I, Hammond GL, Vogl AW, Hayden MR, Leavitt BR (2007). Testicular degeneration in Huntington disease. *Neurobiol Dis*. 26(3): 512-20. Impact: 5.403, Cit: 51.
7. **Van Raamsdonk JM**, Metzler M, Slow E, Pearson JP, Carroll J, Schwab C, Leavitt BR, Hayden MR (2007). Phenotypic Abnormalities in the YAC128 Mouse Model of Huntington Disease are Penetrant on Multiple Genetic Backgrounds and Modulated by Strain. *Neurobiol Dis*. 26(1): 189-200. Impact: 5.403, Cit: 67.
8. Zhang Y, Leavitt BR, **Van Raamsdonk JM**, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM (2006). Huntingtin inhibits caspase-3 activity and mediates differential cellular response. *EMBO J*. 25(24):5896-906. Impact: 9.205, Cit: 64.
9. **Van Raamsdonk JM**, Pearson J, Rogers DA, Murphy Z, Hayden MR, Leavitt BR (2006). Wild-type Huntingtin Ameliorates Striatal Neuronal Atrophy But Does Not Prevent Other Abnormalities in the YAC128 Mouse Model of Huntington Disease. *BMC Neurosci* 7: 80-89. Impact: 3.042, Cit: 39.
10. **Van Raamsdonk JM**, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR (2006). Body Weight is Modulated by Levels of Full-Length Huntingtin. *Hum Mol Gen*. 15(9): 1513-1523. Impact: 7.636, Cit: 59.

11. Leavitt BR, **Van Raamsdonk JM**, Shehadeh J, Fernandes H, Graham RK, Wellington CL, Raymond LA, Hayden MR (2006). Wild-Type Huntingtin Protects Neurons from Excitotoxicity. *J. Neurochem.* 96(4): 1121-9. Impact: 4.061, Cit: 129.
12. **Van Raamsdonk JM**, Murphy Z, Pearson J, Slow EJ, Leavitt BR, Hayden MR (2005). Selective Degeneration and Nuclear Localization of Mutant Huntingtin in the YAC128 Mouse Model of Huntington Disease. *Hum Mol Gen.* 14(24): 3823-35. Impact: 7.636, Cit: 118.
13. **Van Raamsdonk JM**, Pearson J, Rogers DA, Lu G, Hayden MR, Leavitt BR (2005). Ethyl-EPA Treatment Improves Motor Dysfunction, but not Neurodegeneration in HD Mice. *Exp Neurol* 196(2): 266-272. Impact: 4.699, Cit: 57.
14. **Van Raamsdonk JM**, Pearson J, Bailey CDC, Rogers D, Johnson GVW, Hayden MR, Leavitt BR (2005). Cystamine Treatment Ameliorates Striatal Neuropathology in YAC128 Mouse Model of Huntington's Disease. *J. Neurochem.* 95(1): 210-220. Impact: 4.061, Cit: 81.
15. Pinto JT, **Van Raamsdonk J**, Leavitt, BR, Hayden MR, Krasnikov BF, Cooper AJL (2005). Treatment of YAC128 Mice and Their Wild-Type Littermates with Cystamine Does not Lead to Its Accumulation in Plasma or Brain: Implications for the Treatment of Huntington Disease. *J. Neurochem.* 94(4): 1087-101. Impact: 4.061, Cit: 42.
16. **Van Raamsdonk JM**, Pearson J, Rogers D, Bissada N, Vogl AW, Hayden MR, Leavitt BR (2005). Loss of wild type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. *Hum Mol Gen* 10(14): 1379-1392. Impact: 7.636, Cit: 104.
17. **Van Raamsdonk JM**, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR (2005). Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease. *J. Neurosci* 25(16): 4169-80. Impact: 7.115, Cit: 197.
18. Slow, EJ, **Van Raamsdonk JM**, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Yang Y-Z, Bissada N, Li X-J, Simpson EM, Gutekunst C-A, Leavitt BR, Hayden MR (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. *Hum Mol Genet* 12(13): 1555-1567. Impact: 7.636, Cit: 400.
19. **Van Raamsdonk JM**, Cornelius RM, Brash JL, Chang PL (2002). Deterioration of polyamino acid-coated alginate microcapsules in vivo. *J Biomater Sci Polym Ed.* 13(8):863-84. Impact: 1.691, Cit: 18.
20. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, **Van Raamsdonk J**, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR (2002). Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. *J Neurosci.* 22(18):7862-72. Impact: 7.115, Cit: 268.
21. **Van Raamsdonk JM**, Ross CJ, Potter MA, Kurachi S, Kurachi K, Stafford DW, Chang PL (2002). Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics. *J Lab Clin Med.* 139(1):35-42. Impact: 2.986, Cit: 38.
22. **Van Raamsdonk JM**, Chang PL (2000). Osmotic pressure test: A simple, quantitative test to assess the mechanical stability of microcapsules. *J. Biomed. Mat. Res.* 54(2), 264-271. Impact: 2.147, Cit: 65.

REVIEW PUBLICATIONS

---

1. **Van Raamsdonk JM**, Hekimi S (2010). Reactive Oxygen Species and Aging in *Caenorhabditis elegans*: Causal or Casual Relationship? *Antioxidants & Redox Signaling* 13(12): 1911-53. Impact: 8.456
2. **Van Raamsdonk JM**, Warby SC, Hayden MR (2007). Selective neuronal degeneration in YAC Mouse Models of Huntington Disease. *Brain Res Bull* 72(2-3): 124-131. Impact: 2.818
3. **Van Raamsdonk JM** (2006). Loss of function mutations in SIL1 cause Marinesco-Sjögren syndrome. *Clin Genet*. 69(5): 399-400. Impact: 3.128
4. Thiele J, **Van Raamsdonk JM** (2006). Gene discovery in methylmalonic aciduria and homocystinuria. *Clin Genet*. 69(5): 402-403. Impact: 3.128
5. **Van Raamsdonk JM**, Hayden MR, Leavitt BR (2005). Experimental Models of Huntington's Disease. *Drug Discovery Today: Disease Models* 2(4): 291-297. Impact: 6.828
6. **Van Raamsdonk JM** (2003). Mechanism specific treatment of a polyglutamine disorder. *Clin Genet*, 64(5):379-80. Impact: 3.128
7. **Van Raamsdonk J** (2003). Gene discovery in the allelic disorders Smith-McCort Dysplasia and Dyggve-Melchior-Clausen syndrome. *Clin Genet*. 63(6): 460-1. Impact: 3.128
8. **Van Raamsdonk JM** (2002). Re-engineering Dystrophin for gene therapy of Duchenne Muscular Dystrophy. *Clin Genet* 62(1): 24-28. Impact: 3.128
9. **Van Raamsdonk JM** (2002). Treatment of Sickle Cell Disease with anti-sickling gene therapy. *Clin Genet* 61(4): 258-9. Impact: 3.128
10. **Van Raamsdonk JM**, Chang PL (2001). Gene therapy for Hemophilia B. *International Journal of Pediatric Hematology/Oncology* 7(5-6): 347-358. Impact: 0.891
11. **Van Raamsdonk JM** (2001). Oligonucleotide gene repair. *Clin Genet* 60(2), 102-103. Impact: 3.128
12. **Van Raamsdonk JM** (2001). Treating a mouse model for Sly Disease with a novel form of gene therapy. *Clin Genet* 59(4), 217-9. Impact: 3.128
13. Chang PL, **Van Raamsdonk JM**, Hortelano G, Barsoum S, MacDonald NC, Stockley TL (1999). The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. *TIBTECH* 17(2), 78-83. Impact: 9.148



**ABSTRACTS (POSTER AND ORAL PRESENTATIONS)**

---

1. Schaar CE, **Van Raamsdonk JM**. Defining the mechanisms underlying longevity in *C. elegans* mitochondrial mutants. Western Michigan Regional Undergraduate Science Symposium, Grand Rapids, MI, USA (November, 2014).
2. Cooper JF, Dues DJ, Spielbauer, KK, **Van Raamsdonk JM**. Delaying aging is beneficial in *C. elegans* models of Parkinson's disease. Grand Challenges in Parkinson's Disease, Grand Rapids, MI, USA (September, 2014).
3. Spielbauer, KK. **Van Raamsdonk JM**. Development and Characterization of Novel *Caenorhabditis elegans* Models of Parkinson's Disease. Grand Challenges in Parkinson's Disease, Grand Rapids, MI, USA (September, 2014).
4. Machiela E, **Van Raamsdonk JM**. Automated phenotyping of worm models of Huntington's disease for the identification of disease modifiers. Hereditary Disease Foundation Huntington's Disease 2014: Milton Wexler Celebration of Life – Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2014).
5. Cooper J, **Van Raamsdonk JM**. Effect of Parkinson's disease associated genes on dopaminergic neurodegeneration with increasing age. Parkinson's Disease: Genetics, Mechanisms and Therapeutics. Keystone, Colorado, USA (March, 2014).
6. Watson M., **Van Raamsdonk JM**. Defining the role of transcription factors in the longevity of mitochondrial mutants. Michigan *C. elegans* Meeting, Holland, MI, USA (February, 2014).  
\*\*selected for oral presentation
7. Andrews E., **Van Raamsdonk JM**. Stress Resistance and Longevity can be Experimentally Dissociated. Western Michigan Regional Undergraduate Science Symposium, Grand Rapids, MI, USA (November, 2013).
8. **Van Raamsdonk JM**. Beneficial Effect of Genes that Extend Lifespan in Worm Models of Huntington Disease. Molecular Genetics of Aging, Cold Spring Harbor, NY, USA (October, 2012).  
\*\*selected for oral presentation
9. **Van Raamsdonk JM**. Expression of Mutations Implicated in Neurodegenerative Diseases in *Caenorhabditis elegans* Models Results in Quantifiable Phenotypic Abnormalities That Can be Used as Outcome Measures in Screens for Modifying Factors. Hereditary Disease Foundation Huntington's Disease 2012: Milton Wexler Celebration of Life – Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2012).
10. **Van Raamsdonk JM**, Hekimi S. Aging genes modulate phenotypic severity in worm models of polyglutamine toxicity disorders. Gordon Conference on CAG Triplet Repeat Disorders. Barga, Italy (June, 2011).
11. **Van Raamsdonk JM**, Wagner L, Bredy TW, Pearson J, Schwab C, Murphy Z, Devon RS, Lu G, Kobor MS, Hayden MR, Leavitt BR. Huntingtin expression prevents the development of epilepsy in FVB/N mice by reducing seizure induced neurodegeneration. Society for Neuroscience Meeting. San Diego, CA, USA (November, 2010).  
\*\*selected for oral presentation

12. **Van Raamsdonk JM**, Hekimi S. Deletion of all five superoxide dismutase genes markedly increases sensitivity to oxidative stress but does not affect lifespan in *Caenorhabditis elegans*. Molecular Genetics of Aging, Cold Spring Harbor, NY, USA (September, 2010).  
\*\*selected for oral presentation
13. **Van Raamsdonk JM**, Wagner L, Bredy TW, Pearson J, Schwab C, Murphy Z, Devon RS, Lu G, Kobor MS, Hayden MR, Leavitt BR. Huntingtin Protects Against Epilepsy. Hereditary Disease Foundation Huntington's Disease 2010: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2010).
14. **Van Raamsdonk JM**, Hekimi S. The Role of Oxidative Stress in Aging and Age-Onset Neurodegenerative Disease. Canadian Human Genetics Conference, St. Sauveur, Quebec, Canada (April, 2010).
15. **Van Raamsdonk JM**, Hekimi S. Polyglutamine toxicity results in increased sensitivity to oxidative stress but is only mildly exacerbated by loss of antioxidant genes. Gordon Conference on CAG Triplet Repeat Disorders. Waterville Valley, USA (June, 2009).
16. **Van Raamsdonk JM**, Hekimi S. Loss of superoxide dismutase increases sensitivity to oxidative stress but does not decrease lifespan. Aging, Stress, Pathogenesis and Heterochrony: *C. elegans* Topic Meeting #4, Madison, Wisconsin, U.S.A. (August, 2008).
17. **Van Raamsdonk JM**, Hekimi S. Polyglutamine toxicity is not markedly exacerbated by the elimination of individual superoxide dismutases in *C. elegans*. Hereditary Disease Foundation Huntington's Disease 2008: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2008).
18. **Van Raamsdonk JM**, Hekimi S. Using *C. elegans* models to Examine the Role of Oxidative Stress in Disorders of Polyglutamine Toxicity. Canadian Human Genetics Conference, St. Sauveur, Quebec, Canada (April, 2008).
19. **Van Raamsdonk JM**, Rogers D, Pearson J, Schwab C, Lu G, Hayden MR, Leavitt BR. Neuroprotective effect of forced exercise in the YAC128 mouse model of Huntington disease. Hereditary Disease Foundation Huntington's Disease 2006: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2006).
20. **Van Raamsdonk JM**, Metzler M, Slow E, Pearson JP, Carroll J, Schwab C, Leavitt BR, Hayden MR. Phenotypic Abnormalities in the YAC128 Mouse Model of Huntington Disease are Penetrant on Multiple Genetic Backgrounds and Modulated by Strain. Hereditary Disease Foundation Huntington's Disease 2006: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2006).
21. **Van Raamsdonk JM**, Leavitt BR, Hayden MR. Elucidation of Wild-Type Huntingtin Function in YAC Transgenic Mice Over-expressing Full-Length Huntingtin. 47<sup>th</sup> Annual Short Course in Medical and Experimental Mammalian Genetics. Bar Harbor, Maine, USA (July, 2006).
22. **Van Raamsdonk JM**, Murphy Z, Pearson J, Slow EJ, Leavitt BR, Hayden MR. Selective Degeneration and Nuclear Localization of Mutant Huntingtin in the YAC128 Mouse Model of Huntington Disease. World Congress for Huntington Disease. Manchester, England (September, 2005).  
\*\*selected for oral presentation

23. Cooper AJ, Krasnikov BF, Pinto JT, **Van Raamsdonk JM**, Hayden MR, Leavitt BR, Jeitner TM. Transglutaminases in Huntington disease (HD). International Society of Neurochemistry meeting. Innsbruck, Austria (August, 2005).
24. **Van Raamsdonk JM**, Pearson J, Rogers D, Bissada N, Vogl AW, Leavitt BR, Hayden MR. Levels of wild type huntingtin expression modulate motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Gordon Conference on CAG Triplet Repeat Disorders. Mount Holyoke, USA (July, 2005).
25. **Van Raamsdonk JM**, Murphy Z, Hayden MR. Region specific toxicity of mutant huntingtin in human Huntington's disease brain is directly replicated in YAC128 mouse model. American Society of Human Genetics, Toronto, ON, Canada (October, 2004).
26. **Van Raamsdonk JM**, Pearson J, Slow E, Leavitt BR, Hayden MR, Van Raamsdonk JM. Impaired lifespan and cognitive dysfunction in the YAC128 mouse model of Huntington's disease. Hereditary Disease Foundation Huntington's Disease 2004: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2004).
27. **Van Raamsdonk JM**, Rogers D, Pearson J, Lu G, Slow EJ, Hayden MR, Leavitt BR. Pre-clinical trials of experimental therapeutics in the YAC128 transgenic mouse model of Huntington's disease. Hereditary Disease Foundation Huntington's Disease 2004: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2004).
28. Leavitt BR, **Van Raamsdonk JM**, Shehadeh J, Fernandes H, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-Type Huntingtin Protects Neurons from NMDA-Mediated Excitotoxicity. Hereditary Disease Foundation Huntington's Disease 2004: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference, Cambridge, MA, USA (August, 2004).
29. **Van Raamsdonk JM**, Leavitt BR, Slow E, Hayden MR. Therapeutic Trials in the YAC128 Mouse Model of Huntington's Disease. Gordon Conference on CAG Triplet Repeat Disorders. Barga, Italy (May, 2003).
30. Leavitt BR, **Van Raamsdonk JM**, Wellington CL, Fernandes H, Roy S, Raymond LA, Nicholson DW, Hayden MR. Pro-Survival Effects of Wild Type Huntingtin. Gordon Conference on CAG Triplet Repeat Disorders. Barga, Italy (May, 2003).
31. **Van Raamsdonk JM**, Leavitt BR, Slow E, Hayden MR. Therapeutic Trials in the YAC128 Mouse Model of Huntington's Disease. Molecular Mechanisms of Neurodegeneration Meeting. Milan, Italy (May, 2003).
32. Slow E, **Van Raamsdonk J**, Rogers D, Graham R, Bissada N, Oh R, Simpson E, Leavitt B, Hayden MR. Decreased Brain Weight in the YAC128 Huntington Disease Mouse Model. Hereditary Disease Foundation Huntington's Disease 2002: Change Advances and Good News (CAG)<sub>n</sub> Huntington's Disease Research Conference(Hereditary Disease Foundation General Meeting), Cambridge, MA, USA (August, 2002).

33. Leavitt BR, **Van Raamsdonk J**, Slow E, Devon RS, Simpson EM, Hayden MR. Cautionary “Tails”: Genetic Factors Affecting the Behavioral Phenotype of the YAC Transgenic Mouse Model of Huntington Disease. Huntington’s Disease 2002: Change Advances and Good News (CAG)<sub>n</sub> Huntington’s Disease Research Conference(Hereditary Disease Foundation General Meeting), Cambridge, MA, USA (August, 2002).
34. Slow E, **Van Raamsdonk J**, Rogers D, Graham R, Bissada N, Oh R, Simpson E, Leavitt B, Hayden MR. Decreased Brain Weight, Striatal Volume and Striatal Neuron Count in the YAC128 Huntington Disease Mouse Model. Huntington Disease Society of America-Coalition for the Cure, Chicago, IL, USA (April, 2002).
35. Slow E, **Van Raamsdonk J**, Rogers D, Bissada N, Hossain S, Simpson E, Leavitt BR, Hayden MR. Decreased Brain Weight, Striatal Volume and Striatal Neuron Count Subsequent to the Onset of a Motor Co-ordination Deficit in the YAC128 Huntington Disease Mouse Model. Canadian Genetic Diseases Network Meeting, Montreal, Quebec, Canada (April, 2002).
36. Wellington CL, Leavitt BR, **Van Raamsdonk JM**, Deng Y, Oh R, Singaraja R, Roy S, Nicholson DW, Hayden MR. Direct Evidence of Caspase-3 Cleavage of Huntingtin *In Vivo*. Hereditary Disease Foundation – Huntington’s Disease 2000: Change Advances and Good News (CAG)<sub>n</sub> Huntington’s Disease Research Conference, Cambridge, MA, USA (August, 2000).
37. Potter MA, Ross CJD, **Van Raamsdonk JM**, Kurachi K, Stafford DW, Chang PL. Use of Anti-CD4 to Improve Delivery of Recombinant hFIX to Hemophilia B Mice by Microencapsulated Cells. Hemophilia 2000 World Congress. Montreal, Quebec, Canada (July, 2000).
38. Cornelius RM, **Van Raamsdonk JM**, Brash JL, Chang PL. Immunoblot Analysis of Proteins Adsorbed to Alginate Microcapsules Following Incubation with Plasma. 6th World Biomaterials Congress, Kamuela, Hawaii, U.S.A. (May, 2000).
39. **Van Raamsdonk JM**, Stafford DW, Chang PL. Treatment of Hemophilic B Mice with Microencapsulated Non-Autologous Cells. 2nd Annual American Society of Gene Therapy Meeting, Washington, DC, USA (June, 1999).
40. **Van Raamsdonk JM**, Chang PL. The Development of Stronger Microcapsules for Somatic Gene Therapeutics. 5th Internet World Congress on Biomedical Sciences 98 (December, 1998).
41. **Van Raamsdonk JM**, Chang PL. Towards Stronger Microcapsules for Somatic Gene Therapeutics. 5th Ottawa Life Sciences National Conference, Ottawa, ON, Canada (November, 1998).  
\*\*selected for oral presentation

**INVITED PRESENTATIONS**

---

- Oct., 2014      Delaying aging is beneficial in *C. elegans* models of neurodegenerative disease  
Western Michigan University, Department of Biological Sciences
- Jun., 2014      Using *C. elegans* models to define the role of aging in neurodegenerative disease  
Vancouver Worm Meeting, University of British Columbia & Simon Fraser University
- Mar., 2014      The role of aging in Huntington disease  
Grand Valley State University, Department of Chemistry
- Feb., 2014      Using small worms to answer big questions about aging and brain disease.  
Michigan Worm Meeting
- Nov., 2013      Using a small worm to answer big question: insights from *C. elegans* about the aging process.  
Western Michigan Regional Undergraduate Science Research Conference
- Nov., 2013      Aging and stress in the worm *C. elegans*  
Calvin College, Department of Chemistry
- Sept., 2013      The relationship between stress resistance and aging  
Grand Valley State University, Department of Biomedical Sciences
- Sept., 2013      Is stress resistance the key to longevity?  
Hope College, Combined Department of Biology and Chemistry
- Jan., 2013      The complex relationship between reactive oxygen species and aging  
Michigan-Ohio Worm Meeting
- Jan., 2012      Oxidative Stress and Aging: Causal or Casual Relationship?  
Simon Fraser University, Department of Biological Sciences
- Sep., 2012      Using the powerful genetics of *Caenorhabditis elegans* to identify modifying factors for  
neurodegenerative diseases  
Grand Challenges in Parkinson's Disease Symposium